Clarity Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Michelle Parker
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.3% |
| Management average tenure | 1.8yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth
Sep 23
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth
Jan 03We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow
May 29Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth
Aug 24CEO
Michelle Parker
less than a year
Tenure
Ms. Michelle Parker is Executive Director of Clarity Pharmaceuticals Ltd from August 2024 and is its Chief Executive Officer and MD. Ms. Parker joined the Clarity Pharmaceuticals Ltd in June 2018. She serv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 11.1yrs | AU$1.22m | 4.9% A$ 62.8m | |
| Chief Financial Officer | 2.7yrs | AU$273.61k | no data | |
| COO & Non-Independent Executive Director | less than a year | AU$1.02m | 1.35% A$ 17.3m | |
| CEO, MD & Executive Director | no data | no data | 0.34% A$ 4.3m | |
| Chief Scientific Officer | no data | AU$241.43k | 1.89% A$ 24.3m | |
| Director of Corporate Communications. | no data | no data | no data | |
| Head of People & Culture | no data | no data | no data | |
| Executive Vice President of Operations | no data | no data | no data | |
| Chief Medical Officer | no data | no data | no data | |
| Executive Vice President of Clinical Development | less than a year | no data | no data | |
| Company Secretary | no data | AU$268.69k | no data |
1.8yrs
Average Tenure
Experienced Management: CU6's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 11.1yrs | AU$1.22m | 4.9% A$ 62.8m | |
| COO & Non-Independent Executive Director | 5.2yrs | AU$1.02m | 1.35% A$ 17.3m | |
| CEO, MD & Executive Director | less than a year | no data | 0.34% A$ 4.3m | |
| Non-Executive Director | 8.8yrs | AU$86.88k | 5.66% A$ 72.4m | |
| Non-Executive Director | 5.8yrs | AU$86.88k | 0.22% A$ 2.9m | |
| Member of Scientific Advisory Board | 2.6yrs | no data | no data | |
| Lead Independent Non-Executive Director | 14.2yrs | AU$95.72k | 0.056% A$ 712.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.5yrs | no data | no data |
5.0yrs
Average Tenure
Experienced Board: CU6's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 13:28 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Clarity Pharmaceuticals Ltd is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Madeleine Williams | Canaccord Genuity |
| David Stanton | Jefferies LLC |